Financials data is unavailable for this security.
View more
Year on year OncoTherapy Science Inc 's revenues fell -46.24%from 1.13bn to 610.12m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 15.15% reduction in net income from a loss of 1.12bn to a larger loss of 1.29bn.
Gross margin | -30.63% |
---|---|
Net profit margin | -211.47% |
Operating margin | -208.10% |
Return on assets | -93.70% |
---|---|
Return on equity | -144.44% |
Return on investment | -129.70% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at OncoTherapy Science Inc fell by 589.98m. Cash Flow from Financing totalled 671.37m or 110.04% of revenues. In addition the company used 1.23bn for operations while cash used for investing totalled 33.35m.
Cash flow per share | -4.03 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.80 |
---|---|
Tangible book value per share | 2.80 |
More ▼
Balance sheet in JPYView more
Current ratio | 2.99 |
---|---|
Quick ratio | 2.67 |
Total debt/total equity | 0.1295 |
---|---|
Total debt/total capital | 0.1146 |
More ▼